

Where do GOLD and NICE recommend LAMA/LABA and ICS/LAMA/LABA classes within UK COPD indications?

Adapted visual shows, for only GOLD group B and NICE guidance for patients with no asthmatic features or features suggesting steroid responsiveness, the initial and follow-up treatment recommendations. Please refer to individual SmPC before prescribing.

GOLD and NICE recommend classes of medicines, not specific products

Initial maintenance therapy

Limited by symptoms

GOLD Group B: mMRC ≥ 2 , CAT ≥ 10 and 0-1 moderate exacerbation (not leading to hospital admission), offer:
NICE: despite short-acting bronchodilator treatments, offer:

LAMA/LABA

Before starting inhaled therapy GOLD and NICE recommend considering non-pharmacological approaches, such as smoking cessation, pulmonary rehabilitation etc.

A short-acting bronchodilator is recommended by GOLD and NICE for additional immediate symptom relief, if needed.

Indications:

LAMA/LABA: Maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. (LAMA/LABAs are not licensed in the UK to treat or reduce the risk of exacerbations).

ICS/LAMA/LABA: Maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by ICS/LABA or LAMA/LABA. (ICS/LAMA/LABA are not licensed in the UK to treat exacerbations).

Follow-up therapy, if experiencing:

Exacerbations

NICE & GOLD: Check for other causes of exacerbations, assess/optimize non-pharmacological management, check inhaler technique and adherence.

NICE: person has 1 severe or 2 moderate exacerbations in a year, consider:

GOLD: if blood eos ≥ 100 , & patient does not respond to LAMA/LABA, recommend:

ICS/LAMA/LABA

An increase in the incidence of pneumonia, including pneumonia requiring hospitalisation, has been observed in patients with COPD receiving ICS. Health professionals should remain vigilant as the clinical features of pneumonia overlap with the symptoms of COPD.'

Limitations due to symptoms

NICE & GOLD: Check for other causes of dyspnoea, assess / optimise non-pharmacological management, check inhaler technique and adherence.

NICE: Consider 3-month trial. If no improvement, revert to LABA/LAMA

GOLD: Consider switching device or molecules

ICS/LAMA/LABA

LAMA/LABA

GOLD and NICE recommend classes of medicines, not individual products or devices



ANORO ELLIPTA umeclidinium/vilanterol

A maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD³

[Click here](#) for prescribing information and adverse event reporting.

TRELEGY ELLIPTA

fluticasone furoate/umeclidinium/vilanterol

A maintenance treatment for adult patients with moderate to severe COPD not adequately treated on an ICS/LABA or LAMA/LABA⁴

[Click here](#) for prescribing information and adverse event reporting.



Ellipta is the only dry powder inhaler that enable device consistency, whether your patient needs a LAMA/LABA (Anoro; umeclidinium/vilanterol) or an ICS/LAMA/LABA (Trelegy; fluticasone furoate/umeclidinium/vilanterol) ^{3,4}

Based on DPIs licensed for COPD in the UK as of January 2025

Abbreviations

CAT, COPD Assessment Test; EOS, eosinophils; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; mMRC, Modified Medical Research Council Dyspnoea Scale

References

1. COPD in over 16s: diagnosis and management NICE guideline [NG115]. Last updated: July 2019. 2. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2025 Report. 3. Anoro Ellipta, Summary of Product Characteristics. 4. Trelegy Ellipta, Summary of Product Characteristics.

Copyright

GSK-adapted from ©2025 Global Strategy for the Diagnosis, Management and Prevention of COPD. All rights reserved. Use is by express license from the owner.

GSK-adapted from ©NICE 2019. COPD in over 16s: diagnosis and management. Available from www.nice.org.uk/guidance/ng115. All rights reserved. Subject Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this material.

INNOVIVA ANORO Ellipta was developed in collaboration with INNOVIVA Inc

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com